Evidence map›Paper›PMID 28428543›Full record

ArticleScientific reports2017

Microspectrofluorimetry to dissect the permeation of ceftazidime in Gram-negative bacteria.

Anas Allam, Laure Maigre, Julia Vergalli, Estelle Dumont, Bertrand Cinquin, Rodolphe Alves de Sousa, Jelena Pajovic, Elizabeth Pinet, Nikaia Smith, Jean-Philippe Herbeuval and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Frontiers in microbiology · 2019
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Anas AllamUMR8601, LCBPT, CNRS Université Paris Descartes, Paris, France.
Laure MaigreUMR_MD1, Aix Marseille Univ, IRBA, TMCD2 Facultés de Médecine et de Pharmacie, Marseille, France.
Julia VergalliUMR_MD1, Aix Marseille Univ, IRBA, TMCD2 Facultés de Médecine et de Pharmacie, Marseille, France.
Estelle DumontUMR_MD1, Aix Marseille Univ, IRBA, TMCD2 Facultés de Médecine et de Pharmacie, Marseille, France.
Bertrand CinquinDISCO beamline, Synchrotron Soleil, Saint-Aubin, France.
Rodolphe Alves de SousaUMR8601, LCBPT, CNRS Université Paris Descartes, Paris, France.
Jelena PajovicDISCO beamline, Synchrotron Soleil, Saint-Aubin, France.
Elizabeth PinetUMR_MD1, Aix Marseille Univ, IRBA, TMCD2 Facultés de Médecine et de Pharmacie, Marseille, France.
Nikaia SmithUMR8601, LCBPT, CNRS Université Paris Descartes, Paris, France.ORCID http://orcid.org/0000-0002-0202-612X
Jean-Philippe HerbeuvalUMR8601, LCBPT, CNRS Université Paris Descartes, Paris, France.
Matthieu RéfrégiersDISCO beamline, Synchrotron Soleil, Saint-Aubin, France.
Isabelle ArtaudUMR8601, LCBPT, CNRS Université Paris Descartes, Paris, France. isabelle.artaud@parisdescartes.fr.
Jean-Marie PagèsUMR_MD1, Aix Marseille Univ, IRBA, TMCD2 Facultés de Médecine et de Pharmacie, Marseille, France. jean-marie.pages@univ-amu.fr.ORCID http://orcid.org/0000-0001-7092-7977
Aix-Marseille Université · FRDélégation Paris 5 · FRSynchrotron soleil · FRÉcole Normale Supérieure Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A main challenge in chemotherapy is to determine the in cellulo parameters modulating the drug concentration required for therapeutic action. It is absolutely urgent to understand membrane permeation and intracellular concentration of antibiotics in clinical isolates: passing the membrane barrier to reach the threshold concentration inside the bacterial periplasm or cytoplasm is the pivotal step of antibacterial activity. Ceftazidime (CAZ) is a key molecule of the combination therapy for treating resistant bacteria. We designed and synthesized different fluorescent CAZ derivatives (CAZ*, CAZ**) to dissect the early step of translocation-accumulation across bacterial membrane. Their activities were determined on E. coli strains and on selected clinical isolates overexpressing ß-lactamases. The accumulation of CAZ* and CAZ** were determined by microspectrofluorimetry and epifluorimetry. The derivatives were properly translocated to the periplasmic space when we permeabilize the outer membrane barrier. The periplasmic location of CAZ** was related to a significant antibacterial activity and with the outer membrane permeability. This study demonstrated the correlation between periplasmic accumulation and antibiotic activity. We also validated the method for approaching ß-lactam permeation relative to membrane permeability and paved the way for an original matrix for determining "Structure Intracellular Accumulation Activity Relationship" for the development of new therapeutic candidates.

Indexed as

Anti-Bacterial AgentsCeftazidimeCell MembraneGram-Negative BacteriaMicrobial Sensitivity TestsMicrospectrophotometryMolecular StructurePeriplasmPermeabilityAnti-Bacterial AgentsCeftazidime

Identifiers

PMID28428543
PMCPMC5430551
OpenAlexW2606307183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.